Страна: Канада
мова: англійська
Джерело: Health Canada
TIZANIDINE (TIZANIDINE HYDROCHLORIDE)
MYLAN PHARMACEUTICALS ULC
M03BX02
TIZANIDINE
4MG
TABLET
TIZANIDINE (TIZANIDINE HYDROCHLORIDE) 4MG
ORAL
150
Prescription
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Active ingredient group (AIG) number: 0135342001; AHFS:
CANCELLED POST MARKET
2017-01-09
PRODUCT MONOGRAPH PR MYLAN-TIZANIDINE TIZANIDINE HYDROCHLORIDE TABLETS 4 MG ANTISPASTIC AGENT Mylan Pharmaceuticals ULC DATE OF REVISION 85 Advance Road, April 19, 2013 Etobicoke, ON M8Z 2S6 Control number: 161061 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION............................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 3 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 8 DRUG INTERACTIONS ......................................................................................................... 14 DOSAGE AND ADMINISTRATION ..................................................................................... 15 OVERDOSAGE ....................................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 16 STORAGE AND STABILITY ................................................................................................. 18 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 18 PART II: SCIENTIFIC INFORMATION .................................................................................... 19 PHARMACEUTICAL INFORMATION ................................................................................. 19 CLINICAL TRIALS ................................................................................................................. 20 DETAILED PHARMACOLOGY .......................... Прочитайте повний документ